Genetic Engineering and Biotechnology news articles take some time to load
GEN's Julianna LeMieux and IPM's Damian Doherty have spent three full days at the AACR meeting in Chicago. In this video, they give a final update on their takeaways from the meeting, covering industry news and clinical trial results.
In a surprising twist, a control compound called FUS79 shows potent antimicrobial activity against Fusobacterium nucleatum, a gut microbe linked to tumor growth, offering a new path for precision microbiome-targeted therapeutics.
Researchers have developed an innovative method for cultivating a prevalent gut fungus, Fusarium foetens, which can reverse progression of the chronic metabolic liver disease in mice.
Scientists from the Keck School of Medicine at University of Southern California have developed a spectral flow cytometry-based panel for profiling CAR T cells that could be used to optimize their manufacturing, leading to more effective therapies.
The combination of RoosterBio's portfolio of hMSC-based products and processes with Thermo Fisher's advanced therapy GMP contract manufacturing capabilities is designed to offer a new solution for the development and manufacture of hMSC and exosome therapeutics.
Scientists used antibodies from a human donor with a self-induced hyper-immunity to snake venom to develop what they claim is the most broadly effective antivenom to date.
Scientists developed a drug delivery system, GlycoCaging, that studies in mice showed releases drugs exclusively to the lower gut, enabling much lower doses than those currently used to treat inflammatory bowel diseases.
Accurate genomic profiling is essential for clinical decision-making and optimizing treatment recommendations.
Zevaskyn won FDA approval upon Abeona’s second filing of a biologics license application (BLA) for the therapy. The first BLA was rejected last year, through an FDA Complete Response Letter citing chemistry, manufacturing, and controls (CMC) concerns related to Zevaskyn, but not questioning its safety and efficacy as shown in clinical data.
Researchers have identified a new genome incorporation mechanism for LINE-1, the only autonomously active retrotransposon in humans, which leverages the cell cycle. The resulting insights can unlock new avenues for improving cellular defense mechanisms against harmful transposable elements.
FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a CDMO for biologics, vaccines, and advanced therapies. With 30+ years of experience, the company specializes in developing and manufacturing biopharmaceuticals using microbial, mammalian, and host/virus systems.
FRESH technology is being commercialized by FluidForm Bio, a Carnegie Mellon spinout company. Andrew Hudson, PhD, and his team have already demonstrated in an animal model that they can cure type 1 diabetes in vivo.
Siren said proceeds will go toward investigational new drug (IND)-enabling animal studies and clinical-grade production of therapy. Upon FDA approval of an IND application, Siren plans to start on Series B financing as well as start enrolling and dosing patients in a multi-site Phase I/II clinical trial.
AACR's achievement awards and lectureships recognize scientific innovation in basic, translational, clinical, and epidemiological cancer research. Recipients are laboratory researchers, physician-scientists, and population scientists whose contributions have improved cancer diagnosis, prevention, and treatment.
Researchers showed how erythropoietin plays a surprising role in dampening immune system response to cancer. Their studies found that blocking EPO activity converted formerly “cold” liver tumors in mice into “hot” tumors.
---- End of list of Genetic Engineering and Biology News Articles on this page 1 of 2 total pages ----